Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.
Flindr Therapeutics has raised $21.4M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Flindr Therapeutics's investors include V-Bio Ventures, Qbic Fund, Innovatiefonds Noord-Holland, Johnson & Johnson Innovation, Curie Capital.
Flindr Therapeutics is headquartered in Amsterdam, The Netherlands.
Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.
Flindr Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Flindr Therapeutics — Funding & Investors." VCBacked, April 24, 2024, https://www.vcbacked.co/company/flindr-therapeutics. Accessed August 13, 2026.
VCBacked. (2024). Flindr Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/flindr-therapeutics
{{cite web |title=Flindr Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/flindr-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated